What is the recommended management and treatment plan for an adult outpatient with type 2 diabetes mellitus, including diagnosis confirmation, lifestyle modification, glucose monitoring, pharmacologic therapy, cardiovascular/renal risk management, complication screening, and follow‑up?

Outpatient Management and Treatment of Type 2 Diabetes Mellitus

Initial Pharmacotherapy at Diagnosis

Start metformin 500–850 mg once or twice daily with meals at the time of diagnosis, titrating by 500 mg weekly to a minimum of 2 g/day (or equivalent extended-release formulation once daily), and continue indefinitely while tolerated. 1

• Metformin reduces cardiovascular events and all-cause mortality, is low-cost, and has a long-standing safety record. 1, 2
• Check estimated glomerular filtration rate (eGFR) before prescribing; metformin is contraindicated when eGFR < 30 mL/min/1.73 m². 1
• When eGFR is 30–45 mL/min/1.73 m², reduce the metformin dose by approximately 50%. 1
• When eGFR is 45–59 mL/min/1.73 m², monitor renal function every 3–6 months. 1
• Extended-release metformin provides comparable glycemic efficacy with fewer gastrointestinal adverse effects. 1

Concurrent Lifestyle Interventions

• Prescribe ≥150 minutes per week of moderate-intensity aerobic activity plus resistance training on ≥2 non-consecutive days. 1, 2
• Target 5–7% body-weight loss in overweight or obese patients through caloric restriction. 1
• Provide individualized medical nutrition therapy delivered by a registered dietitian. 1
• Limit sodium intake to <2 g/day (≈5 g salt) to support blood-pressure management. 2
• Interrupt sedentary periods lasting ≥30 minutes with brief standing or walking bouts. 2

Immediate Insulin Requirement Assessment

Initiate insulin immediately (with or without additional agents) if any of the following are present: 1

• HbA1c ≥ 9% 1
• Random plasma glucose ≥ 250 mg/dL 1
• Marked symptomatic hyperglycemia (polyuria, polydipsia, weight loss) 1
• Diabetic ketoacidosis or ketosis 1

When insulin is required:

• Start basal insulin (NPH or long-acting analog) at 10 units once daily at bedtime or 0.1–0.2 units/kg body weight. 1
• Titrate by 2–4 units every 3 days until fasting glucose is 80–130 mg/dL without hypoglycemia. 1
• Continue metformin when insulin is added (unless contraindicated) because it lowers insulin requirements and offers cardiovascular benefit. 1

Adding Second-Line Agents Based on Comorbidities

For Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or High ASCVD Risk

Add a GLP-1 receptor agonist (semaglutide, liraglutide, or dulaglutide) to metformin at diagnosis, regardless of baseline HbA1c. 1, 2

• GLP-1 receptor agonists reduce HbA1c by 0.6–0.8% (up to 1.5% with semaglutide), promote 2–5 kg weight loss, and have proven cardiovascular-mortality benefit. 1
• These agents carry minimal hypoglycemia risk when not combined with sulfonylureas or insulin. 1
• GLP-1 receptor agonists are preferred over insulin as the first injectable medication. 3

For Patients with Heart Failure or Chronic Kidney Disease

Add an SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) to metformin at diagnosis, regardless of baseline HbA1c. 3, 1, 2

• SGLT2 inhibitors reduce CKD progression by 24–39%, lower heart-failure hospitalizations, and decrease cardiovascular and all-cause mortality. 1, 2
• Initiate when eGFR ≥ 30 mL/min/1.73 m²; evidence supports continuation down to eGFR ≥ 20 mL/min/1.73 m² for cardiovascular and renal protection. 2
• Educate patients to stop the drug and seek care if nausea, vomiting, or abdominal pain develop (risk of euglycemic diabetic ketoacidosis). 1
• The glycemic benefits of SGLT2 inhibitors are reduced at eGFR <45 mL/min/1.73 m². 3

For Patients with Advanced CKD (eGFR <30 mL/min/1.73 m²)

• A GLP-1 receptor agonist is preferred for glycemic management due to lower risk of hypoglycemia and for cardiovascular event reduction. 3

Glycemic Targets

• Standard target for most adults: HbA1c <7% to balance efficacy with hypoglycemia risk. 3, 1
• More stringent target (HbA1c <6.5%) may be appropriate for patients with short diabetes duration, long life expectancy, no significant cardiovascular disease, and low hypoglycemia risk. 1
• Less stringent target (HbA1c 7.5–8%) is appropriate for patients with a history of severe hypoglycemia, limited life expectancy (<10 years), advanced micro- or macrovascular complications, extensive comorbidities, or long-standing diabetes that is difficult to control. 3, 1

Monitoring and Therapy Intensification

• Reassess HbA1c 3 months after initiating or changing therapy. 1
• If HbA1c remains >7% after 3–6 months of metformin at maximal tolerated dose, add a second agent (GLP-1 receptor agonist, SGLT2 inhibitor, or DPP-4 inhibitor). 1
• Perform HbA1c testing quarterly in patients whose therapy has changed or who are not meeting goals. 1
• Perform HbA1c testing at least twice yearly in patients meeting treatment goals with stable glycemic control. 1
• Do not delay therapeutic intensification beyond 3 months of inadequate control, as delays increase the risk of microvascular complications. 2

Third-Line Therapy

If HbA1c remains above target after 3 months of dual therapy (metformin + one additional agent): 1

• Add a GLP-1 receptor agonist if not already prescribed (preferred third agent due to superior glycemic efficacy, weight loss, and cardiovascular benefit). 1
• Add an SGLT2 inhibitor if not already prescribed and the patient has heart failure or CKD. 3
• Consider a DPP-4 inhibitor (provides 0.5–0.8% HbA1c reduction without cardiovascular benefit) if GLP-1 receptor agonists are not tolerated. 1
• Do not combine GLP-1 receptor agonists with DPP-4 inhibitors; no additional glucose-lowering benefit is observed. 1

Combination Therapy with Insulin

• If insulin is used, combination therapy with a GLP-1 receptor agonist (including dual GIP/GLP-1 receptor agonist) is recommended for greater glycemic effectiveness as well as beneficial effects on weight and hypoglycemia risk. 3
• Insulin dosing should be reassessed upon addition or dose escalation of a GLP-1 receptor agonist. 3
• Continue metformin and other glucose-lowering agents when initiating insulin therapy (unless contraindicated). 3

Diabetes Self-Management Education and Safety Monitoring

• All adults should receive diabetes self-management education (DSME) at diagnosis and as needed thereafter. 1
• DSME should address psychosocial issues because emotional well-being is linked to better diabetes outcomes. 1
• Monitor vitamin B12 levels periodically in patients on long-term metformin, especially if anemia or peripheral neuropathy develop. 3, 1

Complication Screening

• Screen for diabetic retinopathy at diagnosis and annually thereafter. 3
• Screen for nephropathy with urine albumin-to-creatinine ratio and eGFR at diagnosis and annually. 3
• Assess for peripheral neuropathy at diagnosis and annually using monofilament testing and vibration sensation. 3
• Perform comprehensive foot examination at each visit for patients with neuropathy or vascular disease. 3

Cardiovascular Risk Management

• Prescribe moderate-to-high intensity statin therapy for all adults aged 40–75 years with diabetes, independent of baseline LDL or calculated risk. 2
• Target blood pressure <130/80 mmHg using ACE inhibitors or ARBs as first-line agents. 2
• Recommend low-dose aspirin (75–162 mg daily) for secondary prevention in patients with established ASCVD, unless contraindicated. 2

Common Pitfalls to Avoid

• Do not delay metformin initiation while awaiting lifestyle changes; start metformin at diagnosis. 1
• Do not discontinue metformin when adding insulin or other agents unless contraindicated; it remains foundational therapy throughout intensification. 1
• Avoid therapeutic inertia: intensify therapy within 3 months if HbA1c remains above target. 1
• Do not use sulfonylureas as first-line therapy in older adults or those with renal impairment due to high hypoglycemia risk and lack of cardiovascular benefit. 1
• Failing to add SGLT2 inhibitors or GLP-1 receptor agonists based on comorbidities (CKD, ASCVD, heart failure) deprives patients of mortality and morbidity benefits that are independent of glycemic control. 2
• When adding SGLT2 inhibitors or GLP-1 receptor agonists, immediately reduce or discontinue sulfonylureas or long-acting insulins to prevent severe hypoglycemia. 2

De-intensification Criteria

• Consider de-intensifying pharmacologic therapy in patients who achieve HbA1c levels <6.5% by reducing dosage, removing a medication if the patient is receiving more than one, or discontinuing pharmacologic treatment. 3
• Metformin may be continued at lower HbA1c levels given its favorable safety profile, low cost, and lack of hypoglycemia risk. 3